NOVEN
TO PRESENT AT DEUTSCHE BANK |
BackMiami, FL, February
6, 2007 -- Noven Pharmaceuticals, Inc. (NASDAQ: NOVN) today announced
that Robert C. Strauss, its President, CEO & Chairman, is scheduled
to provide an update on Noven’s business and prospects at the
Deutsche Bank Small Cap Growth Conference in Naples, Florida on Tuesday,
February 13, 2007, at 12:00 noon Eastern Time. The public is invited
to listen to the presentation live via webcast at www.noven.com, and
a replay will be available for at least two weeks at the same site.
Noven
Pharmaceuticals, Inc., headquartered in Miami, Florida, is a leading
developer of advanced transdermal drug delivery technologies and prescription
transdermal products. Noven’s prescription patches
are approved in over 30 countries and include Vivelle-Dot™ (the
most prescribed estrogen patch in the U.S.) and Daytrana™ (the
first and only patch approved for the treatment of ADHD). A range of
new patches is under development by Noven in collaboration with industry
partners. Noven is committed to expanding the universe of available
transdermal therapies for the benefit of patients, partners and shareholders.
See www.noven.com for additional information.
Contact: |
Copyright © 2007 Noven Pharmaceuticals, Inc. All rights reserved.